GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » Net Change in Cash

Cronos Group (Cronos Group) Net Change in Cash : $441.45 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cronos Group Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Cronos Group's Net Change in Cash for the three months ended in Mar. 2024 was $185.82 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $441.45 Mil.

Cronos Group Net Change in Cash Historical Data

The historical data trend for Cronos Group's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cronos Group Net Change in Cash Chart

Cronos Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,175.77 -121.67 -191.05 -122.33 -95.35

Cronos Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -350.98 -4.24 162.23 97.64 185.82

Cronos Group Net Change in Cash Calculation

Cronos Group's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-42.835+-59.499+-1.03+8.011
=-95.35

Cronos Group's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-2.204+189.556+-0.645+-0.884
=185.82

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $441.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cronos Group Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Cronos Group's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Cronos Group (Cronos Group) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » Net Change in Cash
Comparable Companies
XCNQ:TRUL TSX:TSND TSX:DHT.U TSX:WEED XCNQ:CL TSX:GUD NEOE:GLAS.A.U NEOE:VRNO XCNQ:AAWH.U TSX:ACB ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
7CI:Germany CRON:Canada
Address
111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1
Website
https://www.thecronosgroup.com
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
Executives
Kamran Khan director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Elizabeth Seegar director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Dominik Meier director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Jason Marc Adler director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2G9
Mcginness James Andrew Iii officer: VP, Controller C/O MARKETWISE, 1125 N. CHARLES STREET, BALTIMORE MD 21201
Maple Holdco (bermuda) Ltd. 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Maple Acquireco (canada) Ulc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Summit Llc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Group, Inc. 10 percent owner 6601 WEST BROAD STREET, RICHMOND VA 23230
James Holm officer: Chief Financial Officer 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Arye Weigensberg officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 MV5 2H1
Doucet Terrence Gregory Joseph officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
John Griese officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Ran Gorelik officer: General Manager (Israel) 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Robert L Madore officer: Chief Financial Officer C/O RALPH LAUREN CORPORATION, 650 MADISON AVENUE, NEW YORK NY 10022